Trying to find your content material...
In-Language Information Contact Us 888-776-0942 from 8 AM - 10 PM ET Information supplied by Might 25, 2022, 23:02 ET Share this text SEONGNAM, South Korea , Might 25, 2022 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology firm centered on growing novel medicine for most cancers, fibrosis and irritation, is scheduled to offer an organization presentation on Thursday, June 16 on the 2022 BIO Worldwide Conference going down in San Diego, California , between June 13 - 16, 2022 .
Pavel Printsev, D irector of Enterprise Improvement, will present an summary of the corporate in addition to an introduction to its clinical-stage belongings: "We're delighted to have the ability to give an in-person presentation at this 12 months's BIO Worldwide convention.
We stay up for the chance to debate our progress and partnering ambitions for therapies which can be addressing critical illnesses with no viable therapy choices," said Pavel Printsev, Director of Enterprise Improvement of Bridge Bio the rapeutics.
To study extra about this session , please go to the occasions web page on our web site at https://bit.ly/3lEGVDY .
About Bridge Biotherapeutics Bridge Biotherapeutics Inc. is a publicly traded clinical-stage biotech firm based mostly within the Republic of Korea with workplaces within the U.S. and China .
Based in 2015, Bridge Biotherapeutics is engaged within the discovery and improvement of novel therapeutics for illness indications with excessive unmet medical wants together with most cancers, ulcerative colitis, and fibrotic illnesses.
The corporate's medical pipeline consists of BBT-401, a first-in-class Pellino-1 inhibitor for the therapy of ulcerative colitis; BBT-877, a novel autotaxin inhibitor for the therapy of fibrotic illnesses together with idiopathic pulmonary fibrosis (IPF); and BBT-176, a potent focused most cancers remedy for non-small cell lung most cancers (NSCLC) with C797S triple EGFR mutations.
Coming into 2022, the corporate enhances its strategic give attention to fibrotic illnesses and cancers.
For extra data, go to https://www.bridgebiorx.com/en/ .
SOURCE Bridge Biotherapeutics, Inc.
Extra information releases in related subjects Cision Distribution 888-776-0942 from 8 AM - 9 PM ET source